Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Astrana Health, Inc. filed an updated corporate investor presentation for September 2026 to be used in upcoming conferences and meetings. The presentation covers the company's business strategy, expansion plans, and financial targets, including its use of artificial intelligence capabilities.
OMNIQ Corp. announced that the U.S. Patent and Trademark Office has granted U.S. Patent No. 12,633,155 B1 for its AI-based vehicle occupancy detection system used in HOV lane enforcement. The technology uses deep-learning and multiband line-scan imagery to automatically count vehicle occupants at highway speeds, addressing a total addressable U.S. market estimated at $218 million.
Summit Therapeutics announced updated overall survival (OS) results from its global Phase III HARMONi trial of ivonescimab in patients with EGFR-mutated non-small cell lung cancer. The updated June 2026 analysis showed a favorable OS hazard ratio of 0.76 in the global population, demonstrating consistent efficacy across both Western and Asian patient subgroups. No new safety signals were observed, reinforcing the potential of ivonescimab as a treatment option following progression on EGFR-targeted therapy.
Scotts Miracle-Gro $250M Debt Financing with JPMorgan Chase Bank, N.A.
Scotts Miracle-Gro redeemed $250 million of its 5.250% Senior Notes due 2026 and renewed its $750 million accounts receivable facility with JPMorgan Chase Bank through August 2027. The company also initiated its $500 million share repurchase program with $25 million in buybacks executed in August and reaffirmed its full-year fiscal 2026 guidance.
BioMarin Pharmaceutical Inc. announced its decision to discontinue the clinical development of VOXZOGO for children with Noonan syndrome. The company cited study feasibility and the current treatment landscape as reasons for the move, noting the decision was not related to safety or efficacy.
Evommune, Inc. has filed an updated corporate presentation as an exhibit to its 8-K, providing a strategic overview of its clinical-stage portfolio including EVO756, EVO301, and EVO646. The presentation outlines the company's focus on chronic inflammatory diseases and highlights its leadership team's track record of approximately 30 approved NDAs and BLAs.
Scholar Rock announced that the FDA has approved ISEMBYLD (apitegromab-mstn) for the treatment of spinal muscular atrophy in adults and children 2 years of age and older. The filing also clarifies that the approval includes a post-marketing requirement for a pregnancy safety study and a request for alert reports regarding bone fractures.
USA TODAY Co., Inc. has appointed Timothy Allen, the current CEO of Babbel, to its Board of Directors, effective September 15, 2026. Mr. Allen will also serve on the Audit and Transformation Committees and will receive standard pro-rated compensation for non-employee directors. The appointment increases the board size from eight to nine members.
AGNT, Inc. completed the repurchase of 8,693,290 shares of its common stock from the Gratitude 2022 Trust for approximately $32 million. The transaction was executed at a 10% discount to the 5-day volume-weighted average price to accelerate the company's capital return program and assist the trust with tax and estate administration.
Aethlon Medical amended the employment agreements for CEO/CFO James B. Frakes and CMO Steven P. LaRosa to modify severance payment terms. In the event of a change in control followed by a qualifying termination, severance and healthcare continuation payments will now be paid as a single lump sum rather than installments. The amendments do not change the total amount of compensation or the conditions required to trigger the benefits.
Otis Worldwide Corporation announced that Judith F. Marks will retire as Chair, CEO, and President effective upon the appointment of her successor, expected in the first half of 2027. The Board has initiated a formal search process for her replacement and entered into a transition agreement where Ms. Marks will serve as a senior advisor through July 31, 2027, to ensure a seamless leadership handover.
Coya Therapeutics announced it has enrolled the 100th patient in its Phase 2/3 ALSTARS trial evaluating COYA 302 for the treatment of ALS. The company expects to complete full enrollment of 120 participants shortly and remains on track to report topline data in early Q2 2027.
Intrusion Inc. and CEO Anthony Scott have mutually agreed not to automatically renew his existing employment agreement when it expires on November 15, 2026. The parties have entered into a structured negotiation period to establish terms for a new agreement, during which Mr. Scott will continue to serve in his current roles at his existing salary and benefits.
Vera Bradley reported second quarter fiscal 2027 consolidated net revenues of $71.6 million, a 1.1% increase year-over-year, driven by 8% growth in its Direct Segment. The company achieved net income of $4.5 million compared to a net loss in the prior year, supported by improved margins and a $7.7 million tariff refund. Management reiterated its full-year sales and operating margin guidance while highlighting a 28% reduction in inventory levels.
Term
Q2 2027
Earnings call
Sep 15, 2026, 8:30 AM ET
“I’m pleased to report that our second quarter results reflect continued momentum in our transformation. This marked our second consecutive quarter of overall revenue growth, with total revenue up 1.1% versus the prior year. The underlying health of our business continued to strengthen across our direct channels, margin structure, and balance sheet.”
Ian Bickley, Chairman and Chief Executive Officer
“Based on our year-to-date performance, we continue to expect year-over-year non-GAAP operating loss improvement of at least 50%. Significant work remains, and we’re encouraged by the progress we’re seeing across all five pillars of our transformation, and we remain committed to returning the business to long-term sustainable growth, profitability, and cash flow generation.”
RB Global announced that its board of directors authorized a $500 million increase to its existing share repurchase program, raising the total aggregate value of the program from $500 million to $1 billion. The Toronto Stock Exchange approved the amendment to the company's normal course issuer bid (NCIB), which allows for the repurchase of up to 10% of the company's public float through March 2027.
LB Pharmaceuticals appointed Susan G. Kozauer, M.D. as Chief Medical Officer, effective September 14, 2026. Her compensation package includes a $515,000 base salary, a 40% target bonus, a $150,000 sign-on bonus, and an inducement grant of 200,000 stock options vesting over four years.
NextTrip announced that its travel-focused media platform, JOURNY TV, will premiere its first original series, 'I DO: In Destination', on October 4 and 5, 2026. The series is a key part of the company's 'content-to-commerce' strategy, designed to integrate travel inspiration with its booking technology. A third episode is scheduled to be filmed in The Bahamas in October 2026 with support from The Bahamas Ministry of Tourism.
Aspen Aerogels filed a formal investor presentation deck on September 15, 2026, to be used for discussions with investors and analysts. The presentation includes the company's financial outlook for the third quarter of 2026 and strategic commentary on its EV thermal barrier and Energy Industrial markets.
Sadot Group Inc. held its 2026 Annual Meeting of Stockholders on September 10, 2026, where shareholders elected five directors to serve until the 2027 annual meeting. Stockholders also approved the Sadot Group Inc. 2026 Stock Incentive Plan, which reserves 3,000,000 shares of common stock for issuance to directors, officers, and employees.
Cheetah Net Supply Chain Service Signs $788K M&A Deal with JoyPak Supply LLC
Cheetah Net Supply Chain Service Inc. entered into a definitive agreement to acquire 100% of the membership interests of JoyPak Supply LLC for $788,000 in cash. JoyPak is a Nevada-based company specializing in the sale of consumer, beauty, and personal care products. The acquisition is intended to diversify Cheetah's product mix and support its long-term growth strategy in new product categories.
Quality Industrial Corp. filed a Certificate of Withdrawal with the State of Nevada to eliminate its Series A Preferred Stock designation. No shares of the Series A Preferred Stock were outstanding at the time of withdrawal, and the shares have been returned to the status of authorized but undesignated preferred stock. This administrative action cleans up the company's capital structure by removing a series of stock that was no longer in use.
Laurida Sayed, Senior Vice President, Chief Accounting Officer and Global Corporate Controller, has resigned effective September 25, 2026, to pursue a new opportunity. Neil Johnston, the company's current CFO, will assume the role of principal accounting officer in addition to his existing duties.
Lindblad Expeditions Holdings Signs $61M M&A Deal with White Desert Ltd, PNR Airways Ltd and Echo Charlie Ltd
Lindblad Expeditions acquired a 60% controlling interest in White Desert and Echo Charlie, pioneers in Antarctic interior expeditions and aviation-based experiential travel, for approximately $61 million in cash. The deal includes options for Lindblad to acquire the remaining 40% in 2030 and 2031 and marks the largest transaction in the company's history, significantly expanding its polar exploration portfolio.
Value
$61M
Counterparty
White Desert Ltd, PNR Airways Ltd and Echo Charlie Ltd
Quantum X Labs appointed Yossi Cohen, the former Director of the Mossad and a strategic advisor to SoftBank, as President of its Scientific Advisory Board. Cohen will help guide the company's technological and commercial roadmap in quantum computing, cybersecurity, and sensing, specifically for defense and aerospace markets. The appointment aims to leverage Cohen's expertise in national security and global technology investments to scale the company's operations.
Zeo ScientifiX announced plans to expand its commercial and provider-support operations into Georgia and Tennessee. The move follows the enactment of new state laws in both jurisdictions that establish frameworks for stem cell and regenerative medicine therapies. The expansion aims to support healthcare providers with biologics, education, and implementation support as they navigate these evolving state-level regulatory environments.
American Express disclosed monthly delinquency and write-off statistics for its U.S. Consumer and U.S. Small Business card portfolios for the period ending August 31, 2026. As of August 31, total card balances held for investment reached $160.3 billion, with net write-off rates of 1.7% for U.S. Consumer and 2.2% for U.S. Small Business. These periodic metrics provide investors with insight into the credit quality and performance of the company's core lending portfolios.
BlossomHill Therapeutics announced updated Phase 1/2 SOLARA trial data for BH-30643 in patients with EGFR C797S-positive NSCLC, showing a 45% objective response rate and 88% disease control rate. The results, presented at the 2026 World Conference on Lung Cancer, demonstrate the drug's potential to overcome resistance to existing EGFR inhibitors in a population with no approved targeted therapies. The company plans to advance the candidate into a Phase 2 trial in 2027 following its recent FDA Fast Track designation.
Counterparty
International Association for the Study of Lung Cancer (IASLC)
Axon Enterprise $1B Debt Financing with JPMorgan Chase Bank, N.A.
Axon Enterprise announced a $1.0 billion offering of 0% convertible senior notes due 2031, with an additional $150 million over-allotment option. Concurrently, the company amended its credit agreement to increase its revolving credit facility from $300 million to $500 million and extended the maturity date to up to five years from closing.
Driven Brands announced that its Board of Directors has authorized a new $100 million share repurchase program, representing approximately 5% of its market capitalization. Alongside the buyback, the company updated its capital allocation strategy to include a long-term net leverage target of 2-3x Net Debt to Adjusted EBITDA while continuing to prioritize growth investments in its Take 5 brand.
FibroBiologics entered into a securities purchase agreement with its Chief Scientific Officer, Hamid Khoja, Ph.D., for a private placement of 298,508 shares and equal warrants. The offering is expected to raise approximately $0.5 million in gross proceeds for general corporate purposes and working capital. The securities were priced at $1.675 per unit, representing the previous day's closing bid price plus a warrant premium.